Prostate cancer is a rapidly moving field when it comes to the treatments that are available. Prostate cancer experts at Mayo Clinic Comprehensive Cancer Center work in an integrated genitourinary practice, which allows them the size and scope they need to drive the entire field forward. At Mayo Clinic, innovative prostate cancer treatments include theranostics, genomics, advanced drug therapies, nuclear medicine imaging, 3D imaging and modeling, and more.
Alan H. Bryce, M.D., Mitchell R. Humphreys, M.D., Ayse T. Kendi, M.D., Carlos E. Vargas, M.D., and their colleagues in Mayo Clinic's genitourinary practice discuss the opportunities that have been made available as the field of prostate cancer quickly advances. prostate cancer right now is a rapidly moving field in terms of the treatment options that are becoming available to patients. Some of the newest things in that field go beyond what we historically thought about for localized treatment such as surgery, radiation therapy. Even some prostate cancers don't need treatment. So we just do active surveillance. We have a very large genital urinary practice comprised of urology, radiation on of medical oncology. We assess the patient's all together as a team and to make sure we are delivering the right treatment at the right time. Some of the newer things that have happened in the prostate cancer space, arthur gnostics, genomics learning more about the cellular A tipi A and the specific gene makeup of those prostate cancers. The most exciting new development for prostate cancer patients is the FDA approval for loutish iUM 1 77 SMA directed therapy. The attraction of this drug is at the seMA molecule takes this radioactive isotope and delivers it precisely directly to the prostate cancer cell, nuclear medicine, imaging detects things at the cellular level at the tissue function level, which can detect things at an earlier stage. And we have also the therapy part use using radioactive materials which are like vectors or props that are this time attached to high energy radionuclides these cells or tissues that we are targeting. Most likely these will be harmful tissues like malignant cells will be destroyed and there will be very little effect on the normal tissues in the realm of radiation therapy. We have been able to see that short courses are as effective or a little bit more effective. The longer courses so we can treat the patient will be faster three D imaging and modeling and prostate cancer is really helped advance what we do surgically. You can see where the bladder is, you can see where the urethra is, you see the prostate and then you can see where that cancer is. So whether it's a focal treatment designed just to destroy that area of the cancer and leave the rest of the process state alone through either high intensity focused ultrasound cryotherapy, interstitial laser therapy or one of the newer modalities and allows the whole team to be on the same page when we're designing and creating treatments for that patient and their prostate cancer specifically. And you know, it's the benefit of the size and scope of the practices that you know, we're really able to cover the field kind of from A to Z to offer each patient and hopefully the best possible option for them. If you were to send a patient here for prostate cancer. The most important thing to think about is that the integrative approach of bringing that whole team to bear on the patient at one time and as a referring provider, we get that information back to you and include you in that conversation because you're part of that patient's healthcare journey. We see our purpose at Mayo clinic as driving the field forward, existing on the cutting edge trying to find those cures